Pfizer Inc.

Enhance global ADC access through acquisition of Seagen

Obtain regulatory approval for HYMPAVZI for treatment of hemophilia A or B with inhibitors from FDA and EMA

Complete BASIS KIDS study to evaluate safety and efficacy of HYMPAVZI in children up to <18 years with hemophilia A or B with or without inhibitors

Evaluate long-term safety and efficacy of HYMPAVZI in hemophilia patients with or without inhibitors in ongoing open-label long-term extension study

Achieve revenues between $59.5 billion and $62.5 billion in 2026

Achieve adjusted EPS between $2.80 and $3 per share in 2026

Establish BRAFTOVI as standard of care for BRAF V600E-mutant metastatic colorectal cancer

Pfizer 2026 revenue guidance midpoint

Pfizer 2026 EPS guidance midpoint

Expand HYMPAVZI indication to include hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients ages 6 to 11 without inhibitors